Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 8/20 | 0.52 |
| ▸ | CHRNA3 | P32297 | 8/20 | 0.52 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 3/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | HPD | P32754 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1357487 | 0.81 | CHRNB4 (0.56) | CHRNB4CHRNA3CHRNA7MAOB | |
| SCHEMBL379281 | 0.78 | MAOB (0.67) | MAOBMRGPRX4CYP4F2CYP4A11BCHE | |
| SCHEMBL2809629 | 0.78 | CHRNB4 (0.52) | CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL2137838 | 0.77 | MRGPRX4 (0.69) | MAOBMRGPRX4CYP4F2CYP4A11BCHE | |
| SCHEMBL2806024 | 0.76 | CHRNB4 (0.57) | CHRNB4CHRNA3CHRNA7MAOB | |
| SCHEMBL5266330 | 0.73 | MAOB (0.49) | MAOBBRD4MRGPRX4CYP4F2CYP4A11 | |
| SCHEMBL30317738 | 0.73 | MAOB (0.49) | MAOBBRD4MRGPRX4CYP4F2CYP4A11 | |
| SCHEMBL3540686 | 0.73 | MAOB (0.46) | MAOBBRD4MRGPRX4CYP4F2CYP4A11 | |
| SCHEMBL2810108 | 0.73 | HRH3 (0.60) | — | |
| SCHEMBL1268719 | 0.73 | MAOB (0.81) | MAOBCYP4F2CYP4A11BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | CHRNB4 1401/4885CHRNA3 2425/4885CHRNA7 2775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.